Effective administration of traditional cytotoxic chemotherapy is often limited by off-target
toxicities. This clinical dilemma is epitomized by cisplatin, a platinating agent, which has …

Purpose: Adverse drug reactions such as ototoxicity, which occurs in approximately one-fifth
of adult patients who receive cisplatin treatment, can incur large socioeconomic burdens on …

Ototoxicity is one of the major side-effects of platinum-based chemotherapy, in particular
cisplatin (cis-diammine dichloroplatinum II). To our knowledge, no systematic review has …

Cisplatin is a highly effective chemotherapeutic. Unfortunately, its use is limited by cisplatin‐
induced ototoxicity (CIO). Substantial research has been performed to uncover the genetic …

Purpose: Cisplatin is one of the most commonly used chemotherapy drugs worldwide and
one of the most ototoxic. We sought to identify genetic variants that modulate cisplatin …

Cisplatin ototoxicity affects different individuals in a widely variable manner. These
variations are likely to be explained by genetic differences among those affected. It would be …

Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying
individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review …

Cisplatin, a platinating agent commonly used to treat several cancers, is associated with
nephrotoxicity, neurotoxicity, and ototoxicity, which has hindered its utility. To gain a better …

Background and propose Cisplatin is a cytotoxic drug that triggers several toxicities.
However, nephrotoxicity and ototoxicity remain major clinical limitations. The aim of our …

Taking a genome-wide association study approach, we identified inherited genetic
variations in ACYP2 associated with cisplatin-related ototoxicity (rs1872328: P= 3.9× 10− 8 …